Eli Lilly weight-loss drug found to address sleep apnoea in trial

Study results could encourage US Medicare system and private insurers to cover tirzepatide treatments... Read more

Bron:

Financial Times - Europe homepage

Tags: Eli Lilly, Medicare

Geplaatst: 17 Apr 2024 - 15:04

Related articles:

Lilly's weight-loss drug reduces sleep apnea severity in late-stage trials (NY Post: National News)
Zepbound shortage update: FDA issues 'limited availability' warning. When might it end? (Fast Company)